Author/Authors :
Carla Spazzolini، نويسنده , , Carla and Mullally، نويسنده , , Jamie and Moss، نويسنده , , Arthur J. and Schwartz، نويسنده , , Peter J. and McNitt، نويسنده , , Scott and Ouellet، نويسنده , , Gregory and Fugate، نويسنده , , Thomas and Goldenberg، نويسنده , , Ilan and Jons، نويسنده , , Christian and Zareba، نويسنده , , Wojciech and Robinson، نويسنده , , Jennifer L. and Ackerman، نويسنده , , Michael J. and Benhorin، نويسنده , , Jesaia and Crotti، نويسنده , , Lia and Kaufman، نويسنده , , Elizabeth S. and Locati، نويسنده , , Emanuela H. and Qi، نويسنده , , Ming and Napolitano، نويسنده , , Carlo and Priori، نويسنده , , Silvia G. and Towbin، نويسنده , , Jeffrey A. and Vincent، نويسنده , , G. Michael، نويسنده ,
Abstract :
Objectives
tudy was designed to evaluate the clinical and prognostic aspects of long QT syndrome (LQTS)-related cardiac events that occur in the first year of life (infancy).
ound
inical implications for patients with long QT syndrome who experience cardiac events in infancy have not been studied previously.
s
udy population of 3,323 patients with QT interval corrected for heart rate (QTc) ≥450 ms enrolled in the International LQTS Registry involved 20 patients with sudden cardiac death (SCD), 16 patients with aborted cardiac arrest (ACA), 34 patients with syncope, and 3,253 patients who were asymptomatic during the first year of life.
s
sk factors for a cardiac event among 212 patients who had an electrocardiogram recorded in the first year of life included QTc ≥500 ms, heart rate ≤100 beats/min, and female sex. An ACA before age 1 year was associated with a hazard ratio of 23.4 (p < 0.01) for ACA or SCD during ages 1 to 10 years. During the 10-year follow-up after infancy, beta-blocker therapy was associated with a significant reduction in ACA/SCD only in those with a syncopal episode within 2 years before ACA/SCD but not for those who survived ACA in infancy.
sions
ts with LQTS who experience ACA during the first year of life are at very high risk for subsequent ACA or death during their next 10 years of life, and beta-blockers might not be effective in preventing fatal or near-fatal cardiac events in this small but high-risk subset.